Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chondroitin sulfate B and vaccine preparation containing same

A chondroitin sulfate and vaccine technology, applied in the field of immunology, can solve the problems of few types of vaccine adjuvants, large toxic and side effects, etc., and achieve the effects of excellent immune effect, small toxic and side effects, and low cost

Inactive Publication Date: 2015-04-08
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the problems of few types of existing vaccine adjuvants and large toxic and side effects, the present invention provides a safe, effective, stable and economical chondroitin sulfate B adjuvant and a vaccine agent containing chondroitin sulfate B adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chondroitin sulfate B and vaccine preparation containing same
  • Application of chondroitin sulfate B and vaccine preparation containing same
  • Application of chondroitin sulfate B and vaccine preparation containing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The dosage of the chondroitin sulfate B adjuvant provided in this example is 5 μg.

[0020] The hepatitis A vaccine containing chondroitin sulfate B adjuvant provided in this example is: add 5 μg of chondroitin sulfate B to each vaccine dose, add chondroitin sulfate B to hepatitis A (HAV) antigen, and then add normal saline to 200 μL , and mix uniformly according to routine to obtain the hepatitis A vaccine agent containing chondroitin sulfate B.

[0021] Wherein, chondroitin sulfate B is a commercially available product, and its molecular formula is (C 14 h 21 NO 14 S) n , with a molecular weight of about 41KDa, purchased from SiGMA, USA; the HAV antigen was a commercially available 18EU HAV antigen solution with a titer of 256EU / ml, purchased from the Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College.

[0022] The immune test and effect of the hepatitis A vaccine that the present embodiment 1 gained contains the cho...

Embodiment 2

[0039] The dosage of the chondroitin sulfate B adjuvant provided in this example is 65 μg.

[0040] The hepatitis A vaccine containing chondroitin sulfate B adjuvant provided in this example is: add 65 μg of chondroitin sulfate B to each vaccine dose, add chondroitin sulfate B to hepatitis A (HAV) antigen, and then add normal saline to 200 μL , and mix uniformly according to routine to obtain the hepatitis A vaccine agent containing chondroitin sulfate B. Wherein, chondroitin sulfate B and HAV antigen are the same as in Example 1;

[0041] The immune test of the hepatitis A vaccine containing the chondroitin sulfate B adjuvant obtained in this example is the same as that in Example 1, and the results are shown in Table 2.

[0042] Table 2 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 16 weeks after using the adjuvant provided in Example 2.

[0043] Table 2

[0044]

[0045] It can be seen from the data analysis that except for the b...

Embodiment 3

[0047] The dosage of the chondroitin sulfate B adjuvant provided in this example is 85 μg.

[0048] The hepatitis A vaccine containing chondroitin sulfate B adjuvant provided in this example is: add 85 μg of chondroitin sulfate B to each vaccine dose, add chondroitin sulfate B to hepatitis A (HAV) antigen, and then add normal saline to 200 μL , and mix uniformly according to routine to obtain the hepatitis A vaccine agent containing chondroitin sulfate B. Wherein, chondroitin sulfate B and HAV antigen are the same as in Example 1;

[0049] The immune test of the hepatitis A vaccine containing the chondroitin sulfate B adjuvant obtained in this example is the same as in Example 1, and the results are shown in Table 3.

[0050] Table 3 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 16 weeks after using the adjuvant provided in Example 3.

[0051] table 3

[0052]

[0053] It can be seen from the data analysis that except for the blan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides an application of chondroitin sulfate B and a vaccine preparation containing the same. The chondroitin sulfate B is used as an adjuvant applied to vaccines, namely each single part of vaccine contains 5-105 micrograms of the chondroitin sulfate B. The chondroitin sulfate B serving as the vaccine adjuvant is small in toxic or side effect, is safe and reliable to use in an immunizing dose range, and can effectively induce humoral immune response with antigenic specificity, and the induced humoral immune response effect is superior to that of an adjuvant-free group. The chondroitin sulfate B is stable in performance and relatively high in biological value, has no toxic effects, and can be added into various conventional vaccines and genetic engineering vaccines to serve as a vaccine adjuvant.

Description

technical field [0001] The invention relates to the application of chondroitin sulfate B and a vaccine agent containing chondroitin sulfate B, belonging to the technical field of immunology. Background technique [0002] In recent years, with the continuous deepening of vaccine research, especially the rapid development of molecular biotechnology, new genetic engineering vaccines have been developed with high purity and strong specificity, but small molecules and relatively weak immunogenicity make it difficult to produce effective immunity. answer. Therefore, it is particularly important to use adjuvants to enhance its immunogenicity. [0003] At present, there are still very few adjuvants that have been approved for use in humans, and aluminum salt adjuvants are one of them. Aluminum salt adjuvants have long been proven in practice to improve antibody levels and safety, but due to their shortcomings such as causing allergies and inducing degenerative neuropathy, there is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61P37/04A61K39/29A61K39/205A61P31/14A61P31/20
CPCY02A50/30
Inventor 王陈芸王海漩孙静李彦涵乌美妮李建芳胡凝珠胡云章施建东
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com